The Second Affiliated Hospital of Kunming Medical University (KMMU Second Hospital), formerly known as Kunming Workers' Hospital, is a leading tertiary-level Grade A comprehensive hospital in Yunnan Province, China. Established in 1952, it has evolved into a healthcare institution integrating medical services, education, research, and public health emergency response, with a strong focus on clinical excellence and regional healthcare leadership .
Basic Information
- Location: The main campus is situated at 374 Dianmian Avenue, Wuhua District, Kunming, Yunnan Province, covering an area of 101.05 mu (approximately 6.7 hectares). It operates a branch, Haikou Hospital, after integrating Yun Guang Hospital in 2021, forming a "one hospital, two campuses" model .
- Status: As a nationally recognized "Top 100 Hospital" and a member of the International SOS Emergency Rescue Network, it serves as a key medical center for critical care, organ transplantation, and trauma treatment in Yunnan .
Medical Services & Facilities
- Clinical Strength: The hospital offers 2,255 open beds across 80 clinical and technical departments. Its nationally accredited key specialties include Critical Care Medicine and Urology, while provincial-level key disciplines cover Burn Surgery, Neurology, Orthopedics, and Rehabilitation Medicine .
- Advanced Technology: Equipped with cutting-edge facilities like the Da Vinci Xi surgical robot and fluorescent laparoscopy, it pioneers minimally invasive surgeries and precision medicine .
- Special Programs: It leads Yunnan in organ transplantation, having performed liver, kidney, and heart transplants since 1999, and established the Yunnan Hepatobiliary and Pancreatic Surgery Hospital and Yunnan Urology Hospital .
Education & Research
- Academic Role: As the Second School of Clinical Medicine of Kunming Medical University, it trains undergraduates, postgraduates, and international students. It hosts 27 national standardized residency training bases and 3 specialist training centers, with 55 doctoral supervisors and 287 master’s supervisors .
- Research Achievements:
- Conducted pivotal Phase II/III clinical trials for Bopidacogene Injection, China’s first gene therapy drug for hemophilia B, which was approved in 2025.
- Secured 63 National Natural Science Foundation projects and 174 provincial-level research grants in recent years .
- Operates 31 academician/expert workstations, 4 provincial clinical medical centers, and advanced research platforms like the Yunnan Key Laboratory of Urinary System Tumors .
International Collaboration
- Belt and Road Initiatives: Actively engages with South and Southeast Asian countries through:
- Sino-Southeast Asian Spine Deformity Prevention and Treatment Alliance, training over 50 surgeons from 23 countries.
- China-Myanmar Cataract Rehabilitation Project and Bridge of Gold International Urology Alliance, hosting international conferences and 援外医疗队 (medical missions to Uganda).
- Alliances: Co-founded the South and Southeast Asian Medical Education and Healthcare Alliance, uniting 56 institutions across 12 countries for collaborative research and talent exchange.
Accreditations & Honors
- Certifications: The Clinical Laboratory has achieved ISO 15189 accreditation.
- Rankings: Ranked 17th in Southwest China for overall medical strength (2025) .
- Recognition: Awarded for its role in advancing medical education and innovation, including a commendation for its contribution to the hemophilia gene therapy trial in 2025.
Community Impact
- Public Health: As Yunnan’s Advanced Stroke Center and Chemical Poisoning Treatment Base, it leads regional emergency response and public health initiatives .
- Patient Care: Handles over 3.75 million outpatient visits annually, with a focus on accessibility and affordability, despite a 2024 penalty for billing irregularities .
In summary, KMMU Second Hospital stands as a regional healthcare hub, blending clinical excellence with innovative research and global collaboration. Its commitment to advancing medical frontiers, particularly in gene therapy and international health partnerships, underscores its role in shaping healthcare in China and beyond.